15 reports

  • Products & Markets
  • TECHNOLOGY & SYSTEMS

High capital intensity is more than $##. ## of capital to $## of labour; medium is $##. ## to $##. ## of capital to $## of labour; low is less than $##. ## of capital for every $## of labour.

  • Addiction Disorder
  • Clinic
  • Mental Health
  • Canada
  • Forecast

High capital intensity is more than $##. ## of capital to $## of labor; medium is $##. ## to $##. ## of capital to $## of labor; low is less than $##. ## of capital for every $## of labor.

  • Addiction Disorder
  • Mental Health
  • Pathology
  • United States
  • Forecast
  • PRODUCTS & SERVICES CONTINUED

High capital intensity is more than $##. ## of capital to $## of labor; medium is $##. ## to $##. ## of capital to $## of labor; low is less than $##. ## of capital for every $## of labor.

  • Addiction Disorder
  • Mental Health
  • United States
  • Demand
  • Forecast
  • DEMAND DETERMINANTS CONTINUED

High capital intensity is more than $##. ## of capital to $## of labour; medium is $##. ## to $##. ## of capital to $## of labour; low is less than $##. ## of capital for every $## of labour.

  • Addiction Disorder
  • Mental Health
  • Pathology
  • Canada
  • Demand

However, researchers have established that biological factors, especially genetic aspects, play an important role.

  • Addiction Disorder
  • World
  • Actavis plc
  • Allergan plc
  • Pfizer Inc.

## ## Phase II ## ## Phase I ## ## IND/ CTA Filed ## ## Preclinical ## ## Discovery ## ## Unknown ## ## Total ## ## Products in Phase II/ III and I/ II are reflected under Phase III and Phase II, respectively Source: Global Markets Direct NUMBER OF PRODUCTS UNDER DEVELOPMENT FOR OPIU

  • Addiction Disorder
  • Opioid
  • United States
  • Product Initiative
  • Addex Therapeutics Ltd
  • 3. GDCT ID is the unique ID of GlobalData's Pharma Intelligence Center clinical trial database

Component ## Naltrexone Effects on Alcohol Reactivity and Consumption, Evaluating the Genetic Variability of Naltrexone Response Effectiveness of Naltrexone Versus Placebo to Reduce Craving for Alcohol With Evaluation of Genetic Variability.

  • Addiction Disorder
  • Antiseptics
  • United States
  • World
  • Alkermes plc

Component ## Naltrexone Effects on Alcohol Reactivity and Consumption, Evaluating the Genetic Variability of Naltrexone Response Effectiveness of Naltrexone Versus Placebo to Reduce Craving for Alcohol With Evaluation of Genetic Variability.

  • Addiction Disorder
  • Antiseptics
  • Neurology
  • Therapy
  • World

When paired with genetic test to focus on the most appropriate patients, AD## was found to significantly reduce days of drinking in patients with certain genotypes.

  • Addiction Disorder
  • Antiseptics
  • United States
  • Product Initiative
  • MediciNova, Inc.

Pharmaceutical companies spend US$## billion on average and ## years to develop a new drug.

  • Addiction Disorder
  • Therapy
  • United States
  • Company Financials
  • Alkermes plc
  • SMALL MOLECULE TO ANTAGONIZE NMDA RECEPTOR AND BLOCK SODIUM CHANNELS FOR CNS DISORDERS - DRUG PROFILE

When paired with genetic test to focus on the most appropriate patients, AD## was found to significantly reduce days of drinking in patients with certain genotypes.

  • Addiction Disorder
  • Antiseptics
  • United States
  • Product Initiative
  • MediciNova, Inc.
  • DRUG ADDICTION - PIPELINE BY OREXIGEN THERAPEUTICS INC
  • DRUG ADDICTION - PIPELINE BY P2D BIOSCIENCE

Ronald Crystal, chairman of the Department of Genetic Medicine at Weill Cornell Medicine and a pulmonologist at NewYork-Presbyterian/ Weill Cornell Medical Center.

  • Addiction Disorder
  • Opioid
  • United States
  • Product Initiative
  • Omeros Corporation
  • DRUG ADDICTION - PIPELINE BY P2D BIOSCIENCE, H2 2017
  • DRUG ADDICTION - PIPELINE BY OREXIGEN THERAPEUTICS INC, H2 2017

P##D Bioscience (P##D) is a pharmaceutical company that develops drugs for genetic orphan diseases.

  • Addiction Disorder
  • Opioid
  • Therapy
  • United States
  • Product Initiative
  • DRUG ADDICTION - PIPELINE BY SANIONA AB, H1 2018
  • DRUG ADDICTION - PIPELINE BY P2D BIOSCIENCE, H1 2018

DRUG ADDICTION - PIPELINE BY OMEROS CORP, H## 2018 OREXIGEN THERAPEUTICS INC DRUG ADDICTION - PIPELINE BY OREXIGEN THERAPEUTICS INC, H## 2018 P##D Bioscience (P##D) is a pharmaceutical company that develops drugs for genetic orphan diseases.

  • Addiction Disorder
  • Therapy
  • United States
  • Company
  • Product Initiative
  • ADDICTION - PIPELINE BY LOHOCLA RESEARCH CORPORATION, H2 2015
  • LOHOCLA RESEARCH CORPORATION

Its products include kin-dolor, genetic marker and genetic markers used for alcoholism and smoking cessation.

  • Addiction Disorder
  • Opioid
  • Research And Development
  • United States
  • Company Operations